WMS Partners’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,555
Closed -$213K 267
2022
Q1
$213K Sell
1,555
-200
-11% -$27.9K 0.03% 237
2021
Q4
$304K Sell
1,755
-10
-0.6% -$1.52K 0.06% 156
2021
Q3
$256K Hold
1,765
0.04% 228
2021
Q2
$233K Sell
1,765
-10
-0.6% -$1.31K 0.03% 233
2021
Q1
$228K Sell
1,775
-363
-17% -$44.7K 0.05% 203
2020
Q4
$255K Hold
2,138
0.04% 207
2020
Q3
$245K Hold
2,138
0.05% 197
2020
Q2
$244K Buy
+2,138
New +$227K 0.05% 187
2020
Q1
Sell
-2,138
Closed -$228K 200
2019
Q4
$228K Sell
2,138
-479
-18% -$50K 0.05% 199
2019
Q3
$280K Buy
2,617
+250
+11% +$25.7K 0.07% 182
2019
Q2
$241K Hold
2,367
0.06% 191
2019
Q1
$213K Buy
+2,367
New +$205K 0.05% 187
2018
Q4
Sell
-2,394
Closed -$258K 195
2018
Q3
$258K Hold
2,394
0.03% 185
2018
Q2
$263K Buy
2,394
+27
+1% +$2.81K 0.03% 177
2018
Q1
$237K Hold
2,367
0.03% 190
2017
Q4
$233K Hold
2,367
0.03% 208
2017
Q3
$222K Hold
2,367
0.03% 193
2017
Q2
$263K Hold
2,367
0.03% 179
2017
Q1
$232K Hold
2,367
0.03% 183
2016
Q4
$218K Sell
2,367
-95
-4% -$8.19K 0.03% 176
2016
Q3
$208K Buy
+2,462
New +$207K 0.03% 180
2015
Q1
Sell
-3,723
Closed -$250K 283
2014
Q4
$250K Buy
+3,723
New +$235K 0.04% 185

Other funds holding DGX

WMS Partners's DGX Position: Q2 2022 in Review

WMS Partners sold out of Quest Diagnostics (DGX) in Q2 2022, closing a stake of 1,555 shares — an estimated $213K sold.

WMS Partners first reported a position in DGX in Q4 2014 and held it in 22 quarters. The position peaked at $304K in Q4 2021. 850 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

  • WMS Partners reported no remaining Quest Diagnostics position as of Q2 2022 after selling out during the quarter.
  • WMS Partners sold 1,555 Quest Diagnostics shares in Q2 2022, an estimated $213K.
  • WMS Partners first reported a position in Quest Diagnostics in Q4 2014 and held it in 22 quarters.
  • WMS Partners's Quest Diagnostics position peaked at $304K in Q4 2021.
  • 850 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on WMS Partners's 13F filing for Q2 2022, filed 5 Aug 2022.